Valuation: Mirum Pharmaceuticals, Inc.

Market Cap 5.2B 4.64B 4.3B 3.91B 7.33B 493B 7.45B 51.54B 20.27B 258B 19.52B 19.12B 824B P/E 2026 *
-5.3x
P/E 2027 * -130x
Enterprise Value 5.39B 4.81B 4.45B 4.05B 7.6B 511B 7.72B 53.41B 21B 267B 20.23B 19.81B 854B EV / Sales 2026 *
7.73x
EV / Sales 2027 * 6.45x
Free-Float
98.32%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Mirum Pharmaceuticals, Inc.

1 day+2.62%
1 week-4.44%
Current month-3.79%
1 month-10.61%
3 months-29.48%
6 months-14.07%
Current year+4.11%
1 week 78.35
Extreme 78.35
87
1 month 77.78
Extreme 77.78
94.57
Current year 73.82
Extreme 73.82
130
1 year 63.23
Extreme 63.232
130
3 years 23.14
Extreme 23.14
130
5 years 12.82
Extreme 12.82
130
10 years 6.51
Extreme 6.5126
130
Manager TitleAgeSince
Chief Executive Officer 47 21/03/2019
Director of Finance/CFO 66 11/09/2023
President 48 16/01/2024
Director TitleAgeSince
Chairman 73 21/03/2019
Director/Board Member 55 07/11/2018
Director/Board Member 47 01/11/2018
Date Insider Type Main position Quantity % Market Cap. Importance
09/10/26 Free

Chief Technology Officer

65,000 0.1001%
06/10/26 Exercice

Founder

24,394 0.0376%
21/09/26 Other

Chief Technology Officer

55 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
+2.62%-4.44%+12.61%+184.57% 5.2B
-1.33%+4.88%+53.33%+109.94% 1,120B
-0.69%-3.77%+31.01%+66.62% 616B
-0.96%+0.55%+21.81%+94.26% 504B
+0.24%+6.23%+33.98%+52.38% 367B
-1.59%-1.25%+66.39%+43.02% 360B
-0.40%+4.28%+19.17%+42.51% 288B
-0.37%+3.35%-1.26%+16.85% 258B
-1.75%+1.76%+40.09%+51.44% 234B
-2.00%+1.75%+24.34%+95.14% 194B
Average -0.28%+2.30%+30.15%+75.67% 394.61B
Weighted average by Cap. -0.52%+3.50%+36.89%+74.62%

Financials

2026 *2027 *
Net sales 698M 622M 576M 524M 983M 66.18B 1B 6.91B 2.72B 34.59B 2.62B 2.56B 111B 820M 731M 677M 616M 1.16B 77.74B 1.17B 8.12B 3.19B 40.63B 3.08B 3.01B 130B
Net income -926M -826M -765M -696M -1.31B -87.83B -1.33B -9.17B -3.61B -45.9B -3.48B -3.4B -147B -28.46M -25.37M -23.5M -21.37M -40.1M -2.7B -40.76M -282M -111M -1.41B -107M -105M -4.51B
Net Debt 189M 168M 156M 142M 266M 17.92B 271M 1.87B 736M 9.37B 709M 694M 29.94B 82.62M 73.65M 68.22M 62.03M 116M 7.83B 118M 818M 322M 4.09B 310M 303M 13.09B
Projected Income Statement - Annual - Mirum Pharmaceuticals, Inc.
Logo Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States, Canada and Japan. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Employees
433
Date Price Change Volume
20/10/26 $82.24 +2.62% 417,820
16/10/26 $80.14 -2.73% 462,948
15/10/26 $82.39 +3.04% 605,245
14/10/26 $79.96 +0.43% 975,117
13/10/26 $79.62 -7.48% 762,633
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Mirum Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
80.14USD
Average target price
153.07USD
Spread / Average Target
+91.01%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Mirum Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. MIRM Stock